Replimune Group (NASDAQ:REPL) Shares Up 6.4% - What's Next?

Replimune Group, Inc. (NASDAQ:REPL - Get Free Report)'s share price rose 6.4% during trading on Wednesday . The stock traded as high as $8.76 and last traded at $8.94. Approximately 291,629 shares were traded during trading, a decline of 66% from the average daily volume of 858,083 shares. The stock had previously closed at $8.40.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on REPL shares. HC Wainwright increased their price objective on shares of Replimune Group from $21.00 to $22.00 and gave the company a "buy" rating in a research report on Thursday, February 13th. JPMorgan Chase & Co. boosted their price objective on shares of Replimune Group from $16.00 to $18.00 and gave the stock an "overweight" rating in a report on Wednesday, February 26th. Finally, BMO Capital Markets upped their price objective on shares of Replimune Group from $18.00 to $27.00 and gave the company an "outperform" rating in a research report on Wednesday, January 22nd. Seven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Buy" and a consensus price target of $19.43.

Replimune Group Stock Performance

The company has a fifty day moving average of $12.27 and a two-hundred day moving average of $12.08. The stock has a market capitalization of $576.84 million, a P/E ratio of -2.44 and a beta of 1.26. The company has a debt-to-equity ratio of 0.14, a current ratio of 11.43 and a quick ratio of 11.43.

Remove Ads

Replimune Group (NASDAQ:REPL - Get Free Report) last posted its quarterly earnings results on Wednesday, February 12th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.70) by ($0.09). On average, equities analysts anticipate that Replimune Group, Inc. will post -2.97 EPS for the current year.

Institutional Investors Weigh In On Replimune Group

Institutional investors and hedge funds have recently bought and sold shares of the business. Sterling Capital Management LLC grew its holdings in shares of Replimune Group by 364.5% during the fourth quarter. Sterling Capital Management LLC now owns 2,109 shares of the company's stock valued at $26,000 after purchasing an additional 1,655 shares during the last quarter. Tower Research Capital LLC TRC grew its stake in Replimune Group by 696.7% during the 4th quarter. Tower Research Capital LLC TRC now owns 6,772 shares of the company's stock worth $82,000 after buying an additional 5,922 shares during the last quarter. Aster Capital Management DIFC Ltd increased its position in Replimune Group by 8,798.9% in the fourth quarter. Aster Capital Management DIFC Ltd now owns 8,276 shares of the company's stock worth $100,000 after buying an additional 8,183 shares during the period. GAMMA Investing LLC lifted its stake in Replimune Group by 897.2% in the first quarter. GAMMA Investing LLC now owns 8,795 shares of the company's stock valued at $902,000 after buying an additional 7,913 shares during the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Replimune Group during the fourth quarter valued at $117,000. Institutional investors and hedge funds own 92.53% of the company's stock.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.